New hope for tough lung cancer: targeted radiation plus immunotherapy tested as maintenance
NCT ID NCT07413042
First seen Feb 27, 2026 · Last updated May 25, 2026 · Updated 12 times
Summary
This early-phase study tests a new combination treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific marker (SSTR). After completing standard first-line therapy, participants will receive a targeted radioactive drug ([225Ac]Ac-DOTATATE) plus an immunotherapy (tislelizumab) as maintenance. The goal is to see if this combination is safe and can help keep the cancer from growing. About 24 adults with good performance status are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.